All posts by: Michael Zand

About Michael Zand

FDA OKs Nationwide Children’s Hospital’s IND for Sarepta’s microdystrophin gene therapy for DMD; shares up 2% – Seeking Alpha

Continue reading

2017-11-06 NEWS

Life Sciences Intellectual Property Review

FDA OKs Nationwide Children’s Hospital’s IND for Sarepta’s microdystrophin gene therapy for DMD; shares up 2%
Seeking Alpha
The FDA has signed off on Nationwide Children’s Hospital’s IND application seeking approval to begin a Phase 1/2a study of evaluating a new gene therapy candidate, AAVrh74.MHCK7.micro-Dystrophin, in patients with Duchenne muscular dystrophy (DMD) …
Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William BlairStreetInsider.com
Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin GeneGlobeNewswire (press release)
Sarepta Therapeutics And Nationwide Children’s Hospital Announce US Food And Drug Administration (FDA …Clinical Leader

all 5 news articles »

Continue reading

2017-11-06 NEWS

Genetic Literacy Project

What’s the excitement over gene therapy?
Genetic Literacy Project
Gene therapy has been in the news a lot of late as a potential cure for a variety of genetic diseases. The biggest breakthrough involved a unanimous backing from U.S. Food and Drug Administration’s advisory panel for a new gene therapy from Spark …

Continue reading

2017-11-06 NEWS

Genetic Literacy Project

What’s the excitement over gene therapy?
Genetic Literacy Project
Gene therapy has been in the news a lot of late as a potential cure for a variety of genetic diseases. The biggest breakthrough involved a unanimous backing from U.S. Food and Drug Administration’s advisory panel for a new gene therapy from Spark …